

## Special Issue

# Plant-Based Bioactive Molecules as Anticancer Drugs/Formulations

### Message from the Guest Editors

Recognizing the loss of millions of cancer patients annually, negating malignant metastatic conditions remains paramount. Accumulating evidence has shown that plant-derived bioactive compounds are promising candidates for inhibition of tumor growth and metastasis, which has a significant influence on tumor progression, the microenvironment, and drug resistance in multifarious cancers. The primary objective of this SI is to describe what we know to date about plant-derived active compounds, application strategies as extracts/drugs or nanoformulations, pharmacologic action, molecular or specific target delivery and bioavailability as cancer therapeutics, and recent trends and gaps in phytochemical-based anticancer drug discovery. Plant-based bioactive molecules that need a special chemical formula in order to determine their anticancer efficacy will be considered. In summary, this SI will describe the promising application of phytochemicals or phytochemotherapy and recent technological interventions against cancer that have the potential to enhance therapeutic effectiveness, reduce the associated side effects, and improve clinical outcomes.

### Guest Editors

Dr. Minaxi Sharma

Haute Ecole Provinciale de Hainaut-Condorcet, Rue Paul Pastur, 7800 Ath, Belgium

Dr. Deepti Diwan

Department of Neurological Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA

### Deadline for manuscript submissions

closed (29 February 2024)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/162874](https://mdpi.com/si/162874)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).